These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24841795)

  • 1. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
    Meininger V; Pradat PF; Corse A; Al-Sarraj S; Rix Brooks B; Caress JB; Cudkowicz M; Kolb SJ; Lange D; Leigh PN; Meyer T; Milleri S; Morrison KE; Orrell RW; Peters G; Rothstein JD; Shefner J; Lavrov A; Williams N; Overend P; Price J; Bates S; Bullman J; Krull D; Berges A; Abila B; Meno-Tetang G; Wurthner J
    PLoS One; 2014; 9(5):e97803. PubMed ID: 24841795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
    Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies.
    Berges A; Bullman J; Bates S; Krull D; Williams N; Chen C
    PLoS One; 2015; 10(2):e0117355. PubMed ID: 25706882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
    Henderson RD; Agosti JM; McCombe PA; Thorpe K; Heggie S; Heshmat S; Appleby MW; Ziegelaar BW; Crowe DT; Redlich GL
    Medicine (Baltimore); 2021 Oct; 100(42):e27421. PubMed ID: 34678870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with stroke.
    Cramer SC; Abila B; Scott NE; Simeoni M; Enney LA;
    Stroke; 2013 May; 44(5):1337-42. PubMed ID: 23471268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting
    Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies.
    Yang Y; Qiu H; Fan Y; Zhang Q; Qin H; Wu J; Zhang X; Liu Y; Zhou R; Zhang Q; Ye Z; Ma J; Xu Y; Feng S; Fei Y; Li N; Cui X; Dong F; Wang Q; Shen K; Shakib S; Williams J; Hu W
    Alzheimers Res Ther; 2024 Oct; 16(1):218. PubMed ID: 39390616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.
    Goldberg A; Geppert T; Schiopu E; Frech T; Hsu V; Simms RW; Peng SL; Yao Y; Elgeioushi N; Chang L; Wang B; Yoo S
    Arthritis Res Ther; 2014 Feb; 16(1):R57. PubMed ID: 24559157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
    Curtin F; Lang AB; Perron H; Laumonier M; Vidal V; Porchet HC; Hartung HP
    Clin Ther; 2012 Dec; 34(12):2268-78. PubMed ID: 23200102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Lim JJ; Derby MA; Zhang Y; Deng R; Larouche R; Anderson M; Maia M; Carrier S; Pelletier I; Girard J; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
    Pegram MD; Borges VF; Ibrahim N; Fuloria J; Shapiro C; Perez S; Wang K; Schaedli Stark F; Courtenay Luck N
    Breast Cancer Res; 2009; 11(5):R73. PubMed ID: 19811637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.
    Choy EH; Bendit M; McAleer D; Liu F; Feeney M; Brett S; Zamuner S; Campanile A; Toso J
    Arthritis Res Ther; 2013 Sep; 15(5):R132. PubMed ID: 24286335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
    Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
    J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.